MYO1G

Summary

MYO1G (myosin IG, HGNC:13880) is a protein-coding gene on chromosome 7p13, encoding Unconventional myosin-Ig (B0I1T2). Unconventional myosin required during immune response for detection of rare antigen-presenting cells by regulating T-cell migration.

MYO1G is a plasma membrane-associated class I myosin (see MIM 601478) that is abundant in T and B lymphocytes and mast cells (Pierce et al., 2001 [PubMed 11544309]; Patino-Lopez et al., 2010 [PubMed 20071333]).

Source: NCBI Gene 64005 — RefSeq curated summary.

At a glance

• GWAS associations: 17
• Clinical variants (ClinVar): 192 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_033054

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13880
Approved symbol	MYO1G
Name	myosin IG
Location	7p13
Locus type	gene with protein product
Status	Approved
Aliases	HA-2
Ensembl gene	ENSG00000136286
Ensembl biotype	protein_coding
OMIM	600642
Entrez	64005

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 8 protein_coding, 4 retained_intron, 2 nonsense_mediated_decay

ENST00000258787, ENST00000463516, ENST00000464434, ENST00000480503, ENST00000483585, ENST00000488554, ENST00000495831, ENST00000648014, ENST00000891370, ENST00000891371, ENST00000946563, ENST00000946564, ENST00000946565, ENST00000946566

RefSeq mRNA: 1 — MANE Select: NM_033054 NM_033054

CCDS: CCDS34629

Canonical transcript exons

ENST00000258787 — 22 exons

Exon	Start	End
ENSE00001923703	44978867	44979015
ENSE00003461267	44970592	44970737
ENSE00003475465	44969413	44969483
ENSE00003481729	44971673	44971789
ENSE00003498126	44962662	44962895
ENSE00003505209	44966073	44966280
ENSE00003518527	44970835	44971059
ENSE00003521761	44964945	44965089
ENSE00003525411	44969705	44969875
ENSE00003537834	44976863	44977071
ENSE00003547153	44972115	44972225
ENSE00003548582	44976564	44976657
ENSE00003562407	44964049	44964162
ENSE00003583127	44962970	44963124
ENSE00003595736	44964415	44964519
ENSE00003623958	44975174	44975227
ENSE00003653492	44965637	44965860
ENSE00003657454	44970040	44970154
ENSE00003666438	44967605	44967737
ENSE00003669681	44975484	44975649
ENSE00003692760	44966672	44966838
ENSE00003693813	44967884	44967958

Expression profiles

Bgee: expression breadth ubiquitous, 203 present calls, max score 98.77.

FANTOM5 (CAGE): breadth broad, TPM avg 25.0962 / max 654.4557, expressed in 524 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
83913	14.0072	443
83914	7.9140	467
83912	2.4557	297
83910	0.2265	83
83915	0.1838	113
83908	0.1782	109
83911	0.0761	40
83909	0.0547	31

Top tissues by expression

240 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	98.77	gold quality
monocyte	CL:0000576	97.51	gold quality
leukocyte	CL:0000738	97.51	gold quality
thymus	UBERON:0002370	97.44	gold quality
blood	UBERON:0000178	94.89	gold quality
lymph node	UBERON:0000029	91.85	gold quality
caecum	UBERON:0001153	91.74	gold quality
vermiform appendix	UBERON:0001154	91.67	gold quality
spleen	UBERON:0002106	91.46	gold quality
pylorus	UBERON:0001166	91.31	gold quality
bone marrow cell	CL:0002092	91.01	gold quality
cardia of stomach	UBERON:0001162	90.86	gold quality
trabecular bone tissue	UBERON:0002483	90.76	gold quality
trachea	UBERON:0003126	90.22	gold quality
bone marrow	UBERON:0002371	89.75	gold quality
nipple	UBERON:0002030	89.49	gold quality
vena cava	UBERON:0004087	89.38	silver quality
superior surface of tongue	UBERON:0007371	88.67	gold quality
pharyngeal mucosa	UBERON:0000355	88.14	gold quality
buccal mucosa cell	CL:0002336	87.70	gold quality
pericardium	UBERON:0002407	87.44	silver quality
tongue	UBERON:0001723	86.88	silver quality
body of tongue	UBERON:0011876	86.49	silver quality
ileal mucosa	UBERON:0000331	86.44	gold quality
pancreatic ductal cell	CL:0002079	85.90	silver quality
subthalamic nucleus	UBERON:0001906	85.52	silver quality
upper lobe of left lung	UBERON:0008952	85.31	gold quality
ventral tegmental area	UBERON:0002691	85.24	silver quality
dorsal plus ventral thalamus	UBERON:0001897	85.20	silver quality
upper lobe of lung	UBERON:0008948	84.84	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-8142	yes	93.09
E-ANND-3	yes	17.12
E-MTAB-7606	no	880.61

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 6)

• Myosin 1G is an abundant class I myosin in lymphocytes whose localization at the plasma membrane depends on its ancient divergent pleckstrin homology (PH) domain (PMID:20071333)
• the information on allele and genotype frequencies of HA-1 and HA-2 in a Taiwanese population (PMID:20509834)
• gene polymorphism does not have any significant effect on the occurrence of GVHD in Tunisia (PMID:20653428)
• Maternal-smoking sensitive CpG sites in newborns were significantly associated with rs61087368 SNP located proximal to MYO1G. (PMID:27403598)
• Detection of Myosin 1g Overexpression in Pediatric Leukemia by Novel Monoclonal Antibodies. (PMID:35409272)
• Activation of MYO1G by lncRNA MNX1-AS1 Drives the Progression in Lung Cancer. (PMID:35819746)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	myo1g	ENSDARG00000036104
mus_musculus	Myo1g	ENSMUSG00000020437
rattus_norvegicus	Myo1g	ENSRNOG00000059140
drosophila_melanogaster	Myo31DF	FBGN0086347
caenorhabditis_elegans		WBGENE00002038

Paralogs (44): MYH13 (ENSG00000006788), MYO16 (ENSG00000041515), MYO9A (ENSG00000066933), MYO3B (ENSG00000071909), MYH7B (ENSG00000078814), MYO15A (ENSG00000091536), MYH7 (ENSG00000092054), MYO3A (ENSG00000095777), MYO9B (ENSG00000099331), MYH9 (ENSG00000100345), MYH14 (ENSG00000105357), MYH1 (ENSG00000109061), MYH3 (ENSG00000109063), MYH2 (ENSG00000125414), MYO1B (ENSG00000128641), MYO5C (ENSG00000128833), CGNL1 (ENSG00000128849), MYH8 (ENSG00000133020), MYH10 (ENSG00000133026), MYH11 (ENSG00000133392), MYO18B (ENSG00000133454), CCDC102A (ENSG00000135736), MYO7A (ENSG00000137474), MYO1F (ENSG00000142347), CGN (ENSG00000143375), TMF1 (ENSG00000144747), MYH15 (ENSG00000144821), MYO10 (ENSG00000145555), CCDC102B (ENSG00000150636), MYO1E (ENSG00000157483), CCDC158 (ENSG00000163749), MYO1A (ENSG00000166866), MYO5B (ENSG00000167306), MYO7B (ENSG00000169994), MYO1H (ENSG00000174527), MYO1D (ENSG00000176658), MYO18A (ENSG00000196535), MYO6 (ENSG00000196586), MYO5A (ENSG00000197535), MYH6 (ENSG00000197616)

Protein

Protein identifiers

Unconventional myosin-Ig — B0I1T2 (reviewed: B0I1T2)

All UniProt accessions (4): A0A3B3IU30, B0I1T2, F8WAS7, F8WEW9

UniProt curated annotations — full annotation on UniProt →

Function. Unconventional myosin required during immune response for detection of rare antigen-presenting cells by regulating T-cell migration. Unconventional myosins are actin-based motor molecules with ATPase activity and serve in intracellular movements. Acts as a regulator of T-cell migration by generating membrane tension, enforcing cell-intrinsic meandering search, thereby enhancing detection of rare antigens during lymph-node surveillance, enabling pathogen eradication. Also required in B-cells, where it regulates different membrane/cytoskeleton-dependent processes. Involved in Fc-gamma receptor (Fc-gamma-R) phagocytosis. Constitutes the minor histocompatibility antigen HA-2. More generally, minor histocompatibility antigens (mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and their expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation (BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. HA-2 is restricted to MHC class I HLA-A*0201.

Subunit / interactions. Interacts with calmodulin; via its IQ motifs.

Subcellular location. Cell membrane. Cell projection. Phagocytic cup.

Tissue specificity. Specifically expressed in hematopoietic cells.

Domain organisation. The myosin tail domain mediates binding to phosphatidylinositol-3,4-bisphosphate (PtdIns(3,4)P2), phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) and phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) and binds to membranous compartments. It is required for recruitment to Fc-gamma receptor (Fc-gamma-R) phagocytic cups.

Similarity. Belongs to the TRAFAC class myosin-kinesin ATPase superfamily. Myosin family.

Isoforms (4)

UniProt ID	Names	Canonical?
B0I1T2-1	1	yes
B0I1T2-2	2
B0I1T2-3	3
B0I1T2-4	4

RefSeq proteins (1): NP_149043* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001609	Myosin_head_motor_dom-like	Domain
IPR010926	Myosin_TH1	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR036072	MYSc_Myo1	Domain
IPR036961	Kinesin_motor_dom_sf	Homologous_superfamily

Pfam: PF00063, PF06017

UniProt features (33 total): mutagenesis site 14, splice variant 5, sequence variant 4, domain 3, sequence conflict 2, chain 1, peptide 1, region of interest 1, binding site 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-B0I1T2-F1	88.42	0.56

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 102–109

Post-translational modifications (1): 1

Mutagenesis-validated functional residues (14):

Position	Phenotype
815	reduced membrane association.
826	reduced membrane association.
876	no effect on membrane localization.
880	no effect on membrane localization.
883	no effect on membrane localization; when associated with r-885.
885	no effect on membrane localization; when associated with k-883.
898	reduced membrane association.
903	no effect on membrane localization; when associated with r-906.
906	no effect on membrane localization; when associated with r-903.
909	no effect on membrane localization.
934	no effect on membrane localization.
945	no effect on membrane localization.
947	no effect on membrane localization.
953	no effect on membrane localization.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 0 (showing top):

GO Biological Process (14): T cell mediated immunity (GO:0002456), exocytosis (GO:0006887), endocytosis (GO:0006897), actin filament organization (GO:0007015), actin filament-based movement (GO:0030048), cell-substrate adhesion (GO:0031589), Fc-gamma receptor signaling pathway involved in phagocytosis (GO:0038096), establishment of localization in cell (GO:0051649), cell gliding (GO:0071976), T cell migration (GO:0072678), T cell meandering migration (GO:0120117), adaptive immune response (GO:0002250), immune system process (GO:0002376), phagocytosis (GO:0006909)

GO Molecular Function (11): microfilament motor activity (GO:0000146), calmodulin binding (GO:0005516), ATP binding (GO:0005524), phosphatidylinositol-4,5-bisphosphate binding (GO:0005546), phosphatidylinositol-3,4,5-trisphosphate binding (GO:0005547), phosphatidylinositol-3,4-bisphosphate binding (GO:0043325), actin filament binding (GO:0051015), nucleotide binding (GO:0000166), cytoskeletal motor activity (GO:0003774), actin binding (GO:0003779), lipid binding (GO:0008289)

GO Cellular Component (13): phagocytic cup (GO:0001891), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), plasma membrane (GO:0005886), microvillus (GO:0005902), actin cytoskeleton (GO:0015629), membrane (GO:0016020), myosin complex (GO:0016459), lamellipodium (GO:0030027), filopodium (GO:0030175), leading edge membrane (GO:0031256), extracellular exosome (GO:0070062), cell projection (GO:0042995)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	6
vesicle-mediated transport	2
phosphatidylinositol phosphate binding	2
phosphatidylinositol bisphosphate binding	2
plasma membrane	2
actin-based cell projection	2
cell leading edge	2
lymphocyte mediated immunity	1
adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains	1
secretion by cell	1
vesicle fusion to plasma membrane	1
vesicle budding from membrane	1
membrane invagination	1
import into cell	1
actin cytoskeleton organization	1
supramolecular fiber organization	1
actin filament-based process	1
cell adhesion	1
Fc receptor mediated stimulatory signaling pathway	1
phagocytosis	1
Fc-gamma receptor signaling pathway	1
establishment of localization	1
cellular localization	1
cell motility	1
lymphocyte migration	1
T cell migration	1
immune response	1
biological_process	1
endocytosis	1
cytoskeletal motor activity	1
polypeptide conformation or assembly isomerase activity	1
ATP-dependent activity	1
protein binding	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
anion binding	1
actin binding	1
protein-containing complex binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1

Protein interactions and networks

STRING

1112 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MYO1G	HLA-A	P01891	749
MYO1G	CENPM	Q9NSP4	720
MYO1G	ARHGAP45	Q92619	692
MYO1G	D6RE68	D6RE68	632
MYO1G	H2AZ2	Q71UI9	623
MYO1G	F2RL3	Q96RI0	606
MYO1G	GFI1	Q99684	597
MYO1G	AHRR	A9YTQ3	596
MYO1G	KRT35	Q92764	595
MYO1G	HMHB1	O97980	571
MYO1G	ATP9A	O75110	526
MYO1G	CNTNAP2	Q9UHC6	523
MYO1G	FRMD4A	Q9P2Q2	511
MYO1G	CYP1A1	P04798	506
MYO1G	A2M	P01023	505

IntAct

27 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
CFTR	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
CD177	MYO1G	psi-mi:“MI:0914”(association)	0.350
CFTR	MYH7B	psi-mi:“MI:0914”(association)	0.350
AFG2A	ESYT2	psi-mi:“MI:0914”(association)	0.350
AFG2B	MMP24OS	psi-mi:“MI:0914”(association)	0.350
NXT2	MYO1G	psi-mi:“MI:0914”(association)	0.350
ATF3	TMEM223	psi-mi:“MI:0914”(association)	0.350
CASP3	TMEM223	psi-mi:“MI:0914”(association)	0.350
CTNNA1	MYO1G	psi-mi:“MI:0914”(association)	0.350
FOS	TMEM223	psi-mi:“MI:0914”(association)	0.350
CTNNA1	EFCAB5	psi-mi:“MI:0914”(association)	0.350
FOS	MYO1G	psi-mi:“MI:0914”(association)	0.350
TFRC	MYO1G	psi-mi:“MI:0403”(colocalization)	0.350
CD247	DDX1	psi-mi:“MI:0914”(association)	0.350
MYO1G	ACTB	psi-mi:“MI:0403”(colocalization)	0.270
MYO1G	hemB	psi-mi:“MI:0915”(physical association)	0.000
napF	MYO1G	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (14): MYO1G (Affinity Capture-MS), MYO1G (Affinity Capture-MS), MYO1G (Affinity Capture-MS), MYO1G (Affinity Capture-MS), MYO1G (Affinity Capture-MS), MYO1G (Proximity Label-MS), MYO1G (Affinity Capture-MS), MYO1G (Affinity Capture-MS), MYO1G (Affinity Capture-MS), MYO1G (Affinity Capture-RNA), MYO1G (Affinity Capture-MS), RALA (Co-fractionation), TFRC (Co-fractionation), MYO1G (Affinity Capture-MS)

ESM2 similar proteins: A0MP03, A2AQP0, A5PF48, A7E2Y1, B0I1T2, D3ZJP6, E7F9L8, F1PRN2, F4IUG9, F4JM19, F8VQB6, O00159, O88329, O94832, P08799, P10568, P79114, P91443, P97479, Q01989, Q03479, Q0WPU1, Q13402, Q17LW0, Q17R14, Q1EG27, Q23978, Q23979, Q27966, Q29P71, Q5SUA5, Q5SYD0, Q5ZLA6, Q5ZMC2, Q622K8, Q63355, Q63357, Q6GPA1, Q6PIF6, Q8K3H5

Diamond homologs: A0MP03, A1C4A5, A1DBH2, A2R5J1, A3LYL7, A4RE77, A5DKH0, A5E4A8, A5PF48, A6SED8, A6ZMG6, A6ZZJ1, A7EK16, A7TDZ8, A8N2Y6, A8PWF6, B0CRJ3, B0I1T2, B0Y9Q4, D3ZJP6, E7F9L8, E9Q634, F1PRN2, F4HWY6, F4I5Q6, F4IUG9, F4IVR7, F4JM19, F4K5J1, K7U9N8, O00159, O00160, O43795, O88329, O94832, P0CP00, P0CP01, P10568, P10569, P19706

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

192 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	168
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3830 predictions. Top by Δscore:

Variant	Effect	Δscore
7:44962965:CTCA:C	donor_loss	1.0000
7:44962966:TCA:T	donor_loss	1.0000
7:44962967:CACCC:C	donor_loss	1.0000
7:44962968:AC:A	donor_gain	1.0000
7:44962968:ACC:A	donor_gain	1.0000
7:44962968:ACCCC:A	donor_loss	1.0000
7:44962969:CC:C	donor_gain	1.0000
7:44962969:CCC:C	donor_gain	1.0000
7:44963121:TCAC:T	acceptor_gain	1.0000
7:44963122:CAC:C	acceptor_gain	1.0000
7:44963122:CACC:C	acceptor_gain	1.0000
7:44963123:AC:A	acceptor_gain	1.0000
7:44963123:ACCT:A	acceptor_loss	1.0000
7:44963124:CC:C	acceptor_gain	1.0000
7:44963124:CCTG:C	acceptor_loss	1.0000
7:44964044:CTCA:C	donor_loss	1.0000
7:44964045:TCA:T	donor_loss	1.0000
7:44964047:A:AC	donor_gain	1.0000
7:44964048:C:CC	donor_gain	1.0000
7:44964048:CCG:C	donor_gain	1.0000
7:44964939:ACTTA:A	donor_loss	1.0000
7:44964940:CTTA:C	donor_loss	1.0000
7:44964943:A:AC	donor_gain	1.0000
7:44964944:C:CT	donor_gain	1.0000
7:44964944:CA:C	donor_gain	1.0000
7:44964944:CAGA:C	donor_gain	1.0000
7:44965086:CCAC:C	acceptor_gain	1.0000
7:44965087:CAC:C	acceptor_gain	1.0000
7:44965087:CACC:C	acceptor_gain	1.0000
7:44965090:C:CC	acceptor_gain	1.0000

AlphaMissense

6656 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:44966818:G:C	C601W	1.000
7:44970612:G:C	F399L	1.000
7:44970612:G:T	F399L	1.000
7:44970614:A:G	F399L	1.000
7:44970625:T:A	D395V	1.000
7:44970625:T:G	D395A	1.000
7:44975562:A:C	F162L	1.000
7:44975562:A:T	F162L	1.000
7:44975564:A:G	F162L	1.000
7:44967957:A:C	Y526D	0.999
7:44970116:A:G	L419P	0.999
7:44970122:T:A	E417V	0.999
7:44970124:G:C	N416K	0.999
7:44970124:G:T	N416K	0.999
7:44970127:G:C	C415W	0.999
7:44970133:G:C	N413K	0.999
7:44970133:G:T	N413K	0.999
7:44970616:C:T	G398D	0.999
7:44970617:C:G	G398R	0.999
7:44970624:G:C	D395E	0.999
7:44970624:G:T	D395E	0.999
7:44970625:T:C	D395G	0.999
7:44970626:C:G	D395H	0.999
7:44970628:A:G	L394P	0.999
7:44975189:G:C	F201L	0.999
7:44975189:G:T	F201L	0.999
7:44975191:A:G	F201L	0.999
7:44975560:C:T	G163D	0.999
7:44975567:G:T	R161S	0.999
7:44975568:G:C	S160R	0.999

dbSNP variants (sampled 300 via entrez): RS1000136151 (7:44962433 GA>G), RS1000273935 (7:44974444 C>A,T), RS1000654347 (7:44967387 C>G,T), RS1000796542 (7:44980143 A>G), RS1000835092 (7:44963683 G>C), RS1000881819 (7:44968421 C>G), RS1001552666 (7:44980038 G>A,T), RS1001583675 (7:44979746 G>A), RS1001698038 (7:44973772 A>G), RS1002222526 (7:44968928 G>A), RS1002224491 (7:44972411 T>C), RS1002233646 (7:44974086 C>T), RS1002272536 (7:44965822 C>A,T), RS1002391502 (7:44963211 C>A,G,T), RS1002397803 (7:44978512 A>G)

Disease associations

OMIM: gene MIM:600642 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

17 associations (top):

Study	Trait	p-value
GCST004608_90	Granulocyte percentage of myeloid white cells	2.000000e-09
GCST004609_31	Monocyte percentage of white cells	7.000000e-15
GCST004610_159	White blood cell count	4.000000e-20
GCST004613_109	Sum neutrophil eosinophil counts	3.000000e-11
GCST004614_101	Granulocyte count	3.000000e-11
GCST004620_74	Sum basophil neutrophil counts	4.000000e-11
GCST004626_103	Myeloid white cell count	3.000000e-10
GCST004627_40	Lymphocyte count	2.000000e-23
GCST004629_115	Neutrophil count	4.000000e-11
GCST005024_13	Pursuit maintenance gain	3.000000e-06
GCST007158_3	Refractive astigmatism	6.000000e-06
GCST007856_14	Colorectal cancer or advanced adenoma	6.000000e-06
GCST90002379_148	Basophil count	4.000000e-09
GCST90002388_388	Lymphocyte count	3.000000e-50
GCST90002394_194	Monocyte percentage of white cells	1.000000e-30
GCST90002398_426	Neutrophil count	4.000000e-18
GCST90002407_549	White blood cell count	3.000000e-37

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0007997	granulocyte percentage of myeloid white cells
EFO:0007989	monocyte percentage of leukocytes
EFO:0004833	neutrophil count
EFO:0004842	eosinophil count
EFO:0007987	granulocyte count
EFO:0005090	basophil count
EFO:0004587	lymphocyte count
EFO:0008433	pursuit maintenance gain measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5724621 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

3 potent at pChembl≥5 of 3 total, top 3 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.66	Kd	2.174	nM	CHEMBL3752910
8.66	ED50	2.174	nM	CHEMBL3752910
6.80	IC50	160	nM	MOLIBRESIB

PubChem BioAssay actives

2 with measured affinity, of 8 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149894: Binding affinity to human MYO1G incubated for 45 mins by Kinobead based pull down assay	kd	0.0022	uM
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2179026: Inhibition of MYO1G (unknown origin) incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	ic50	0.1600	uM

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases methylation, increases expression	4
Tobacco Smoke Pollution	increases methylation	2
Aflatoxin B1	increases methylation	2
aristolochic acid I	increases expression	1
GSK-J4	decreases expression	1
bisphenol A	decreases expression	1
sulforaphane	decreases expression	1
sodium arsenite	increases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
di-n-butylphosphoric acid	affects expression	1
(+)-JQ1 compound	decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Cotinine	affects methylation	1
Diuron	decreases expression	1
Methapyrilene	increases methylation	1
Nickel	increases expression	1
Smoke	decreases expression	1
Tretinoin	increases expression	1
Urethane	decreases expression	1
Valproic Acid	decreases methylation	1
Antirheumatic Agents	decreases expression	1
Okadaic Acid	increases expression	1
Particulate Matter	increases abundance, increases expression	1

ChEMBL screening assays

7 unique, capped per target: 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652936	Binding	Binding affinity to human MYO1G incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.